HK1004087A1 - Chloropyrimidine intermediates - Google Patents

Chloropyrimidine intermediates

Info

Publication number
HK1004087A1
HK1004087A1 HK98103336A HK98103336A HK1004087A1 HK 1004087 A1 HK1004087 A1 HK 1004087A1 HK 98103336 A HK98103336 A HK 98103336A HK 98103336 A HK98103336 A HK 98103336A HK 1004087 A1 HK1004087 A1 HK 1004087A1
Authority
HK
Hong Kong
Prior art keywords
intermediates
processes
chloropyrimidine
chloropyrimidine intermediates
aminopurines
Prior art date
Application number
HK98103336A
Other languages
English (en)
Inventor
Mary Susan Daluge
Tolar Michael Martin
Joanne Michelle Ferry Fugeet
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749873&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1004087(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Found filed Critical Wellcome Found
Publication of HK1004087A1 publication Critical patent/HK1004087A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Catalysts (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Indole Compounds (AREA)
  • Liquid Crystal Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HK98103336A 1994-02-04 1998-04-21 Chloropyrimidine intermediates HK1004087A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9402161A GB9402161D0 (en) 1994-02-04 1994-02-04 Chloropyrimidine intermediates
PCT/GB1995/000225 WO1995021161A1 (en) 1994-02-04 1995-02-03 Chloropyrimide intermediates

Publications (1)

Publication Number Publication Date
HK1004087A1 true HK1004087A1 (en) 1998-11-13

Family

ID=10749873

Family Applications (1)

Application Number Title Priority Date Filing Date
HK98103336A HK1004087A1 (en) 1994-02-04 1998-04-21 Chloropyrimidine intermediates

Country Status (28)

Country Link
US (8) US6448403B1 (xx)
EP (1) EP0741710B1 (xx)
JP (1) JP3670012B2 (xx)
KR (1) KR100355983B1 (xx)
CN (2) CN1161343C (xx)
AT (1) ATE192742T1 (xx)
AU (1) AU690203B2 (xx)
BR (1) BR9506667A (xx)
DE (1) DE69516847T2 (xx)
DK (1) DK0741710T3 (xx)
ES (1) ES2148486T3 (xx)
FI (1) FI112477B (xx)
GB (1) GB9402161D0 (xx)
GR (1) GR3033850T3 (xx)
HK (1) HK1004087A1 (xx)
HU (1) HU223096B1 (xx)
IL (1) IL112539A (xx)
MX (1) MX9603091A (xx)
MY (1) MY113775A (xx)
NO (1) NO310819B1 (xx)
NZ (1) NZ278948A (xx)
PL (1) PL183885B1 (xx)
PT (1) PT741710E (xx)
RU (1) RU2140913C1 (xx)
SG (1) SG47918A1 (xx)
TW (1) TW390877B (xx)
WO (1) WO1995021161A1 (xx)
ZA (1) ZA95884B (xx)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) * 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation
SK285228B6 (sk) * 1997-05-13 2006-09-07 Lonza Ag Spôsob výroby racemického alebo opticky aktívnehoderivátu 4-(hydroxymetyl)-2-cyklopenténu a racemicky N-butyryl-1-amino-4- (hydroxymetyl)-2-cyklopentén
GB9721780D0 (en) * 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
WO1999021861A1 (en) * 1997-10-24 1999-05-06 Glaxo Group Limited Process for preparing a chiral nucleoside analogue
JP2001522850A (ja) * 1997-11-12 2001-11-20 グラクソ グループ リミテッド キラルヌクレオシド類似体の製造法
SK284594B6 (sk) * 1997-11-27 2005-07-01 Lonza Ag Spôsob výroby derivátov aminoalkoholov a ich soli
EP1188750B1 (de) * 1998-12-21 2003-10-15 Lonza AG Verfahren zur Herstellung von 2,5-Diamino-4,6-dihalogenpyrimidinen
CA2440809A1 (en) * 2001-03-01 2002-09-12 Conforma Therapeutics Corp. Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
US20070129334A1 (en) * 2001-10-30 2007-06-07 Conforma Therapeutics Corporation Orally Active Purine-Based Inhibitors of Heat Shock Protein 90
AU2002343604C1 (en) * 2001-10-30 2009-09-17 Conforma Therapeutics Corporation Purine analogs having HSP90-inhibiting activity
US6780635B2 (en) 2001-12-27 2004-08-24 Council Of Scientific And Industrial Research Process for the preparation of optically active azabicyclo heptanone derivatives
KR100573859B1 (ko) * 2002-07-15 2006-04-25 경동제약 주식회사 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의제조방법
US7560231B2 (en) * 2002-12-20 2009-07-14 Roche Molecular Systems, Inc. Mannitol and glucitol derivatives
US20040266795A1 (en) * 2003-04-30 2004-12-30 Genny Shamai Process for the preparation of famciclovir
WO2004103979A1 (ja) * 2003-05-26 2004-12-02 Sumitomo Chemical Company, Limited Ｎ－（２－アミノ－４，６－ジクロロピリミジン－５－イル）ホルムアミドの製造方法
KR100573860B1 (ko) * 2003-06-13 2006-04-25 경동제약 주식회사 2-아미노-9-(2-치환에틸)푸린을 이용한 9-[4-아세톡시-3-(아세톡시메틸)부트-1-일]-2-아미노푸린의 제조방법
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
KR100573861B1 (ko) * 2003-07-18 2006-04-25 경동제약 주식회사 2-아미노-9-(2-할로게노에틸)푸린 및 그 중간체로서의 2-아미노-6,8-디클로로-9-(2-히드록시에틸)푸린의 제조방법
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1556383A1 (en) * 2003-09-04 2005-07-27 Teva Pharmaceutical Industries Ltd. Process for preparing famciclovir
CN101906106A (zh) * 2003-09-18 2010-12-08 康福玛医药公司 作为hsp90-抑制剂的新的杂环化合物
DE102004002055A1 (de) * 2004-01-15 2005-08-11 Degussa Ag Verfahren zur Herstellung von 2-Amino-4,6-dichlor-5-formamidopyrimidin
MX2007002043A (es) * 2004-08-16 2007-10-11 Quark Biotech Inc Usos terapeuticos de los inhibidores del rtp801.
US7544672B2 (en) * 2005-03-30 2009-06-09 Conforma Therapeutics Corporation Alkynyl pyrrolo[2,3-d]pyrimidines and related analogs as HSP90-inhibitors
GB2426247A (en) 2005-05-20 2006-11-22 Arrow Int Ltd Methods of preparing purine derivatives such as famciclovir
EP1937258A2 (en) * 2005-09-23 2008-07-02 Conforma Therapeutics Corporation Anti-tumor methods using multi drug resistance independent synthetic hsp90 inhibitors
EP1857458A1 (en) * 2006-05-05 2007-11-21 SOLMAG S.p.A. Process for the preparation of abacavir
CN100465174C (zh) * 2006-06-13 2009-03-04 中国科学院上海有机化学研究所 制备光学纯阿巴卡韦的方法
WO2008072074A1 (en) * 2006-12-11 2008-06-19 Aurobindo Pharma Limited An improved process for the preparation of purine derivative
EP1939196A1 (en) * 2006-12-21 2008-07-02 Esteve Quimica, S.A. Process for the preparation of abacavir
US20100137592A1 (en) * 2007-06-21 2010-06-03 Asif Parvez Sayyed Process for preparing purine derivative
EP2085397A1 (en) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Crystalline form of abacavir
DK3494972T3 (da) 2010-01-27 2024-01-29 Viiv Healthcare Co Kombinationer af dolutegravir og lamivudin til behandling af HIV-infektion
CZ305457B6 (cs) 2011-02-28 2015-09-30 Ústav organické chemie a biochemie, Akademie věd ČR v. v. i. Pyrimidinové sloučeniny inhibující tvorbu oxidu dusnatého a prostaglandinu E2, způsob výroby a použití
WO2014133085A1 (ja) 2013-02-27 2014-09-04 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104672239A (zh) * 2013-11-26 2015-06-03 上海迪赛诺化学制药有限公司 一种采用一锅法制备阿巴卡韦式v中间体的工艺
CN109456329B (zh) * 2018-11-19 2021-03-09 迪嘉药业集团有限公司 一种泛昔洛韦的制备方法
CN113292507B (zh) * 2021-06-25 2022-07-19 潍坊奥通药业有限公司 一种2-氨基-6-氯鸟嘌呤及其中间体的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0141927B1 (en) 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
EP0182024B1 (en) 1984-09-20 1991-04-03 Beecham Group Plc Purine derivatives and their pharmaceutical use
US4965270A (en) 1987-05-30 1990-10-23 Beecham Group P.L.C. Purine derivatives
GB8724765D0 (en) 1987-10-22 1987-11-25 Beecham Group Plc Process
US4916224A (en) 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB2243609B (en) * 1988-01-20 1992-03-11 Univ Minnesota Dideoxydidehydrocarbocyclic pyrimidines
US5631370A (en) 1988-01-20 1997-05-20 Regents Of The University Of Minnesota Optically-active isomers of dideoxycarbocyclic nucleosides
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB8916698D0 (en) 1989-07-21 1989-09-06 Beecham Group Plc Novel process
GB8918827D0 (en) 1989-08-17 1989-09-27 Beecham Group Plc Novel compounds
MY104575A (en) 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
CZ287049B6 (cs) 1992-01-22 2000-08-16 Lonza A. G. N-5-chráněné 2,5-diamino-4,6-dichlorpyrimidiny a způsob jejich přípravy
GB9402161D0 (en) * 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
CA2145928C (en) 1994-04-27 2007-10-09 Gerhard Stucky N-(2-amino-4,6-dichloropyrimidin-5-yl)formamide, and a process for its preparation

Also Published As

Publication number Publication date
MX9603091A (es) 1998-01-31
WO1995021161A1 (en) 1995-08-10
US5917041A (en) 1999-06-29
HUT75300A (en) 1997-05-28
DK0741710T3 (da) 2000-08-14
SG47918A1 (en) 1998-04-17
CN1388123A (zh) 2003-01-01
FI112477B (fi) 2003-12-15
PL183885B1 (pl) 2002-07-31
DE69516847D1 (de) 2000-06-15
PT741710E (pt) 2000-09-29
IL112539A (en) 2000-08-31
NO310819B1 (no) 2001-09-03
US6555687B1 (en) 2003-04-29
US6552193B1 (en) 2003-04-22
CN1139924A (zh) 1997-01-08
MY113775A (en) 2002-05-31
ATE192742T1 (de) 2000-05-15
FI963070A0 (fi) 1996-08-02
BR9506667A (pt) 1997-09-16
US5917042A (en) 1999-06-29
US20020173649A1 (en) 2002-11-21
US6448403B1 (en) 2002-09-10
CN1105109C (zh) 2003-04-09
EP0741710B1 (en) 2000-05-10
GB9402161D0 (en) 1994-03-30
ZA95884B (en) 1996-08-05
US6870053B2 (en) 2005-03-22
JP3670012B2 (ja) 2005-07-13
AU690203B2 (en) 1998-04-23
KR100355983B1 (ko) 2002-12-28
NZ278948A (en) 1998-01-26
JPH09508412A (ja) 1997-08-26
CN1161343C (zh) 2004-08-11
AU1543895A (en) 1995-08-21
NO963239L (no) 1996-10-02
IL112539A0 (en) 1995-05-26
NO963239D0 (no) 1996-08-02
TW390877B (en) 2000-05-21
DE69516847T2 (de) 2000-10-26
HU9602114D0 (en) 1996-09-30
US20030187263A1 (en) 2003-10-02
US6087501A (en) 2000-07-11
ES2148486T3 (es) 2000-10-16
FI963070A (fi) 1996-08-02
PL315713A1 (en) 1996-11-25
RU2140913C1 (ru) 1999-11-10
EP0741710A1 (en) 1996-11-13
GR3033850T3 (en) 2000-10-31
HU223096B1 (hu) 2004-03-29

Similar Documents

Publication Publication Date Title
GB9402161D0 (en) Chloropyrimidine intermediates
ZA9710098B (en) Halogenopyrimidines.
AP1411A (en) Pyrrolo[2,3d] pyrimidine compositions and their use.
BG101110A (en) Substituted pyrimidine compounds and their application
AU9744298A (en) Substituted tetrahydronaphthaline and analogous compounds
DE69905170D1 (en) Thiazolopyrimidinderivate
MX9700885A (es) Nuevas heteroariloxazolidinonas.
GB0111186D0 (en) Novel compounds
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
GB9425730D0 (en) Compounds
DE69521122T2 (de) 2,3,4,5-tetrahydro-1h-3-benzazepin säure-additions-salze
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
ATE294802T1 (de) 3-alkylimidazopyridine
MX9804068A (es) Nuevos derivados de quinoxalindiona, su preparacion y empleo en medicamentos.
CA2182105A1 (en) Chloropyrimide intermediates
IL124354A0 (en) Hemoregulatory compounds
TW282449B (xx)

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20150202